Receptor tyrosine kinases (RTKs) family is comprised of different cell surface glycoproteins.
These enzymes participate in and regulate vital processes such as cell proliferation, polarity …

Approximately 30 therapeutic monoclonal antibodies have already been approved for
cancers and inflammatory diseases, and monoclonal antibodies continue to be one of the …

Receptor tyrosine kinases (RTKs) represent a large class of protein kinases that span the
cellular membrane. There are 58 human RTKs identified which are grouped into 20 distinct …

Signaling pathways mediated by receptor tyrosine kinases (RTKs) and their ligands play
important roles in the development and progression of human cancers, which makes RTK …

In recent years, monoclonal antibodies have become important weapons in the arsenal of
anticancer drugs, and in select cases are now the drugs of choice due to their favorable …

Introduction. Recently, monoclonal antibodies (mAbs) have become powerful human
therapeutics in the diagnosis and treatment of many diseases. Drugs based on mAbs are …

Targeting receptor tyrosine kinases by therapeutic monoclonal antibodies and antibody-
drug conjugates has met with tremendous success in clinical oncology. Currently, numerous …

The therapeutic arsenal in solid tumors comprises different anticancer strategies with
diverse chemotherapeutic agents and a growing number of biological substances. Large …

Monoclonal antibodies (mAbs) have always provided outstanding therapeutic arsenal in the
treatment of cancer, be it hematological malignancies or solid tumors. Monoclonal …

An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells
or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy …